ATE483815T1 - Expressionskonstrukte mit mehreren rna-polymerase-iii-promotoren - Google Patents

Expressionskonstrukte mit mehreren rna-polymerase-iii-promotoren

Info

Publication number
ATE483815T1
ATE483815T1 AT05810305T AT05810305T ATE483815T1 AT E483815 T1 ATE483815 T1 AT E483815T1 AT 05810305 T AT05810305 T AT 05810305T AT 05810305 T AT05810305 T AT 05810305T AT E483815 T1 ATE483815 T1 AT E483815T1
Authority
AT
Austria
Prior art keywords
polymerase iii
expression constructs
iii promoters
rna polymerase
multiple rna
Prior art date
Application number
AT05810305T
Other languages
English (en)
Inventor
Catherine J Pachuk
Daniel E Mccallus
Chandrasekhar Satishchandran
Martin D Sigg
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE483815T1 publication Critical patent/ATE483815T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05810305T 2004-08-23 2005-08-23 Expressionskonstrukte mit mehreren rna-polymerase-iii-promotoren ATE483815T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60362204P 2004-08-23 2004-08-23
US62994204P 2004-11-22 2004-11-22
PCT/US2005/029976 WO2006033756A2 (en) 2004-08-23 2005-08-23 Multiple rna polymerase iii promoter expression constructs

Publications (1)

Publication Number Publication Date
ATE483815T1 true ATE483815T1 (de) 2010-10-15

Family

ID=36090440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05810305T ATE483815T1 (de) 2004-08-23 2005-08-23 Expressionskonstrukte mit mehreren rna-polymerase-iii-promotoren

Country Status (8)

Country Link
US (2) US7985581B2 (de)
EP (3) EP2169072A1 (de)
JP (1) JP4804467B2 (de)
AT (1) ATE483815T1 (de)
AU (1) AU2005287365B2 (de)
CA (1) CA2577519A1 (de)
DE (1) DE602005024015D1 (de)
WO (1) WO2006033756A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
JP4980716B2 (ja) * 2003-06-12 2012-07-18 アルナイラム ファーマシューティカルズ， インコーポレイテッド 遺伝子サイレンシングに有用な保存されたｈｂｖ及びｈｃｖ配列
AU2016202897A1 (en) * 2004-12-22 2016-05-19 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
ATE507293T1 (de) * 2004-12-22 2011-05-15 Alnylam Pharmaceuticals Inc Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
JP2008237023A (ja) * 2005-07-15 2008-10-09 Univ Of Tokyo 多重ｓｈＲＮＡ発現ベクター
WO2008147430A2 (en) * 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
ES2434169T3 (es) 2006-11-08 2013-12-13 Veritas Bio, Llc Entrega in vivo de ARN bicatenario a una célula objetivo
WO2008148068A1 (en) * 2007-05-23 2008-12-04 Mannkind Corporation Multicistronic vectors and methods for their design
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
CA2839896A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
WO2013036879A1 (en) * 2011-09-08 2013-03-14 Gradalis, Inc. Compositions and methods for treating prostate cancer
WO2013067050A1 (en) 2011-10-31 2013-05-10 University Of Utah Research Foundation Genetic alterations in glioblastoma
CN104394892B (zh) * 2012-05-15 2020-02-14 北京命码生科科技有限公司 植物作为功能microRNA和/或功能siRNA运载体、制备方法及其应用
WO2015048690A1 (en) * 2013-09-27 2015-04-02 The Regents Of The University Of California Optimized small guide rnas and methods of use
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11339437B2 (en) * 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
DK3116997T3 (da) 2014-03-10 2019-08-19 Editas Medicine Inc Crispr/cas-relaterede fremgangsmåder og sammensætninger til behandling af lebers kongenitale amaurose 10 (lca10)
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
US20180291382A1 (en) * 2014-11-05 2018-10-11 The Regents Of The University Of California Methods for Autocatalytic Genome Editing and Neutralizing Autocatalytic Genome Editing
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
WO2016141243A1 (en) * 2015-03-03 2016-09-09 The Regents Of The University Of California Enzymatic modification of nucleic acids
TWI554608B (zh) * 2015-03-27 2016-10-21 Univ China Medical A nucleic acid sequence segment for enhancing protein expression, an expression vector comprising a sequence segment thereof, and a kit comprising its expression vector
WO2017177029A1 (en) * 2016-04-06 2017-10-12 Duke University Compositions and methods for enhanced gene expression and viral replication
AU2017305404B2 (en) 2016-08-02 2023-11-30 Editas Medicine, Inc. Compositions and methods for treating CEP290 associated disease
EP3496727A4 (de) * 2016-08-12 2020-03-18 The Regents of the University of California Konstrukte und verfahren zur signalverstärkung
EP4035659A1 (de) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosome zur ausgabe von therapeutischen wirkstoffen
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
DK3768846T3 (da) * 2018-03-21 2023-07-24 Aldevron L L C Virale og ikke-virale nanoplasmidvektorer med forbedret produktion
AR114551A1 (es) 2018-08-13 2020-09-16 Alnylam Pharmaceuticals Inc COMPOSICIONES DE AGENTES DE ARNhd CONTRA EL VIRUS DE HEPATITIS B (HBV) Y MÉTODOS PARA SU USO
WO2020160121A1 (en) * 2019-01-29 2020-08-06 The General Hospital Corporation Oligonucleotides and methods for the treatment of age-related macular degeneration

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643771A (en) 1980-05-19 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Non-reverting live bacterial vaccines
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5547862A (en) 1993-07-29 1996-08-20 Ambion Inc. Vectors containing multiple promoters in the same orientation
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
EP0728202A4 (de) 1993-11-12 1997-04-23 Univ Case Western Reserve Episomales expressionsvektor für die menschliche gentherapy
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5585263A (en) 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5932241A (en) 1995-06-07 1999-08-03 Valentis, Incorporated Cationic lipid DNA complexes for gene targeting
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
AU7450496A (en) 1995-10-20 1997-05-07 Collagen Corporation Production of recombinant procollagen in yeast
US5851804A (en) 1996-05-06 1998-12-22 Apollon, Inc. Chimeric kanamycin resistance gene
DE69738514D1 (de) * 1996-11-08 2008-03-27 Neose Technologies Inc Verbesserte expressionsvektoren
US5874242A (en) * 1997-03-19 1999-02-23 University Of Georgia Research Foundation, Inc. Efficient translation in eukaryotic and prokaryotic systems
CA2306733A1 (en) 1997-10-28 1999-05-06 American Home Products Corporation Compositions and methods for delivery of genetic material
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2323179A1 (en) 1998-03-16 1999-09-23 The Procter & Gamble Company Method of reducing cellulite in mammalian skin
KR20070118315A (ko) 1999-04-21 2007-12-14 와이어쓰 폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
JP2003269028A (ja) 2002-03-18 2003-09-25 Aisin Seiki Co Ltd ドアロック解除装置
JP4868739B2 (ja) 2002-05-06 2012-02-01 アルナイラム ファーマシューティカルズ， インコーポレイテッド 核酸の送達法
WO2004011624A2 (en) 2002-07-31 2004-02-05 Nucleonics, Inc. Double stranded rna structures and constructs, and methods for generating and using the same
US7303906B2 (en) 2002-09-06 2007-12-04 Wisconsin Alumni Research Foundation Competent bacteria
AU2003284323A1 (en) 2002-10-18 2004-05-04 Alnylam Pharmaceuticals Inc Double-stranded rna structures and constructs, and methods for generating and using the same
AU2004214954A1 (en) 2003-02-27 2004-09-10 Alnylam Pharmaceuticals, Inc. Methods and constructs for evaluation of RNAi targets and effector molecules
JP4980716B2 (ja) 2003-06-12 2012-07-18 アルナイラム ファーマシューティカルズ， インコーポレイテッド 遺伝子サイレンシングに有用な保存されたｈｂｖ及びｈｃｖ配列
US20050130184A1 (en) 2003-07-18 2005-06-16 University Of Massachusetts Enhanced promoters for synthesis of small hairpin RNA
US20050130919A1 (en) 2003-07-18 2005-06-16 University Of Massachusetts Regulatable promoters for synthesis of small hairpin RNA
CA2536026A1 (en) 2003-08-22 2005-05-06 Nucleonics Inc. Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments
US20060171924A1 (en) 2003-10-03 2006-08-03 Ke Luo Bidirectional promoters for small RNA expression
WO2005111219A1 (en) 2004-04-16 2005-11-24 University Of Washington METHODS AND VECTORS FOR EXPRESSING siRNA

Also Published As

Publication number Publication date
JP4804467B2 (ja) 2011-11-02
DE602005024015D1 (de) 2010-11-18
EP1784492A2 (de) 2007-05-16
EP2270161A2 (de) 2011-01-05
EP2169072A1 (de) 2010-03-31
EP1784492B1 (de) 2010-10-06
CA2577519A1 (en) 2006-03-30
US7985581B2 (en) 2011-07-26
US20090298909A1 (en) 2009-12-03
US20120028348A1 (en) 2012-02-02
WO2006033756A3 (en) 2007-01-18
JP2008510489A (ja) 2008-04-10
AU2005287365B2 (en) 2011-02-10
AU2005287365A1 (en) 2006-03-30
WO2006033756A2 (en) 2006-03-30
EP2270161A3 (de) 2011-02-02

Similar Documents

Publication Publication Date Title
ATE483815T1 (de) Expressionskonstrukte mit mehreren rna-polymerase-iii-promotoren
ATE528402T1 (de) Effiziente genabschaltung in pflanzen unter verwendung von kurzen dsrna-sequenzen
JP2019503394A5 (de)
JP2017093448A5 (de)
RU2017130143A (ru) Гибридные днк/рнк-полинукдеотиды crispr и способы
JP2014514921A5 (de)
EP2434020A3 (de) Verfahren zur Herstellung eines Negativstrang-RNA-Virusvektors unter Verwendung eines Hybridpromotors mit Cytomegalovirus Enhancer und aviärem Beta-Actin-Promotor
JP2005517427A5 (de)
RU2013135484A (ru) Молекулы нуклеиновых кислот, которые придают устойчивость к насекомым-вредителям отряда жестокрылых
WO2006041290A3 (en) Nucleic acids against viruses , in particular hiv
WO2011056005A3 (ko) 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도
ATE551420T1 (de) Gentransfer und expression mit hoher effizienz in säugerzellen mittels eines mehrfachtransfektionsverfahrens von matrixbindungsbereichsequenzen
JP2006502694A5 (de)
NZ599237A (en) Sirna compounds comprising terminal substitutions
MX2011007693A (es) Metodos para amplificar acidos nucleicos del virus de hepatitis c.
JP2008500817A5 (ja) Ｄｎａウイルスのマイクロｒｎａ及びそれを阻害する医薬品
WO2006045590A3 (en) Multidomain rna molecules comprising at least one aptamer for delivering double stranded rna to pest organisms
EA201070108A1 (ru) Cd44 сплайс-варианты в нейродегенеративных заболеваниях
RU2014121304A (ru) Ингибирование экспрессии вирусных генов
DE602004032245D1 (de) Genabschaltung (Gene silencing) durch hybride Sens-DNA und Antisens-RNA Konstrukte, gekoppelt an ein Peptid zur erleichterten Aufnahme in Zellen
WO2004044134A3 (en) Phosphorous-linked oligomeric compounds and their use in gene modulation
JP2005537028A5 (de)
JP2006523103A5 (de)
JP2012085645A5 (de)
US20220348909A1 (en) Allosteric Conditional Guide RNAs for Cell-Selective Regulation of CRISPR/Cas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties